SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
(Amendment No. )
[ X] Filed by the Registrant
[ ] Filed by a party other than the Registrant
Check the appropriate box:
[ ] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
[ ] Definitive Proxy Statement
[X ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to (S)240.14a-11(c) or (S)240.14a-12
INVESCO GLOBAL HEALTH SCIENCES FUND
Payment of Filing Fee (Check the appropriate box):
[X ] No fee required
[ ] $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1), 14a-6(i)(2) or
Item 22(a)(2) of Schedule 14A
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11/
1. Title of each class of securities to which transaction applies:
------------------------------------------------------------------------
2. Aggregate number of securities to which transaction applies:
------------------------------------------------------------------------
3. Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
filing fees calculated and state how it was determined):
------------------------------------------------------------------------
4. Proposed maximum aggregate value of transaction:
------------------------------------------------------------------------
5. Total fee paid:
------------------------------------------------------------------------
[ ] Fee paid previously by written preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
1. Amount Previously Paid:
------------------------------------------------------------------------
2. Form Schedule or Registration Statement No.
------------------------------------------------------------------------
3. Filing Party:
------------------------------------------------------------------------
4. Date Filed:
------------------------------------------------------------------------
INVESCO GLOBAL HEALTH SCIENCES FUND INVESCO Funds Group, Inc.
Investment Division
7800 East Union Avenue
Suite 1100
Denver, Colorado 80237
Telephone: 303-930-2400
PRESS RELEASE For more information,
please contact:
Molly Cisneros, 303-930-6540
Director Investor Relations
INVESCO GLOBAL HEALTH SCIENCES FUND PROXY STATEMENT CORRECTION
July 28, 1998, Denver, Colorado - With the concurrence of Advantage Partners,
L.P., INVESCO Global Health Sciences Fund (NYSE: GHS) (the "Fund") has announced
a correction to the Fund's proxy statement dated July 23, 1998 for its Annual
Meeting of Shareholders to be held on August 27, 1998. The second full paragraph
on page 13 of the proxy statement, which was part of the statement presented by
Advantage Partners, L.P. in support of its shareholder proposal, unfortunately
contained an error, which Fund Management regrets. That paragraph of the
supporting statement by Advantage Partners, L.P. should read as follows:
The Board resisted shareholder suggestions over the years to open-end the
fund yet never provided any economic justification for inaction on the $100
million discount problem. In our opinion, retaining the closed-end
structure is more helpful to Invesco's approximately $5 million in annual
management fees than it is for shareholder returns. We urge you to see
through the attempt that is made to oppose our proposal.
The INVESCO Global Health Sciences Fund is a diversified closed-end investment
company managed by INVESCO Funds Group, Inc. Its investment objective is to seek
capital appreciation by investing substantially all of its assets in equity and
related securities of U.S. and foreign companies presently engaged in the
development, production and distribution of products and services related to the
health sciences.
# # # # #